How cost-effective are ovarian and breast cancer risk reduction strategies among women with pathogenic variants in individual cancer susceptibility genes (ie, BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BRIP1)? Here, BRCA2 is linked to breast carcinoma.